Colon cancer IVD test

Based on tumor autoantibody biomarkers


BioVendor, AIT Austrian Institute of Technology, and SCIENION are collaborating to jointly develop an in-vitro diagnostic test kit for colon cancer. The innovative test based on tumor autoantibody biomarkers shall identify cancer at an early stage.

Colon cancer is one of the most common cancers being the second most common cause of cancer in women and the third most common in men. Early detection of this serious disease increases both the therapeutic success and the chance of survival. The current diagnostic practice involves either uncomfortable invasive procedures or uses stool tests, the latter resulting in a high percentage of false-positive results.

AIT provides their previously identified and patented biomarkers, specific for blood-based diagnosis of colon cancer. BioVendor, represented by its subsidiary company TestLine Clinical Diagnostics, will bring in its development expertise and distribution network. SCIENION contributes with its longstanding expertise in the microarray market and will be responsible for assay development and manufacturing using the company’s high-quality microtiter plates (sciPLEXPLATES).

Besides joint R&D efforts, BioVendor Laboratorni medicina benefits from using SCIENION’s integrated product portfolio for developing and producing their unique immunoassays – including the sciFLEXARRAYER dispenser configured with the sciDROP PICO option, consumables such as sciPLEXPLATES, as well as the sciREADER CL2 for detection of assay results.

“We are spotting sensitive biological materials such as antigens and antibodies. Temperature is one of the factors that can have an impact of the functionality of these molecules. For us it is an important benefit of the sciFLEXARRAYER that the spotting head does not produce heat – especially as we manufacture tests in large quantities. Furthermore, SCIENION offers a cooling unit for source plates and targets.

Dr. Viktor Růžička, CEO of BioVendor Laboratorni medicina a.s.

“We are entering the cooperation with BioVendor and SCIENION extremely enthusiastic and we strongly believe that the newly formed consortium has the power to perfectly drive forward AITs breakthrough biomarker technologies into market-ready solutions.”

Dr. Martin Weber, Head of Molecular Diagnostics at AIT